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Abstract
Detection of sentinel lymph node (SLN) using photoacoustic imaging is an emerging technique for
noninvasive axillary staging of breast cancer. Due to the absence of intrinsic contrast inside the lymph
nodes, exogenous contrast agents are used for photoacoustic detection. In this work, we have
demonstrated near infrared detection of SLN with gold nanobeacons (GNB) providing the
photoacoustic contrast in a rodent model. We found that size dictates the in vivo characteristics of
these nanoparticles in SLN imaging. Larger nanobeacons with high pay loads of gold were not as
efficient as smaller size nanobeacons with lower pay loads for this purpose. Colloidal GNBs were
designed as a nanomedicine platform with “soft” nature that is amenable to bio-elimination, an
essential feature for in vivo efficacy and safety. The GNBs were synthesized as lipid- or polymer-
encapsulated colloidal particles incorporating tiny gold nanoparticles (2–4 nm) in three tunable sizes
(90 nm, 150 nm and 290 nm). Smaller GNBs were noted trafficking through the lymphatic system
and accumulating more efficiently in the lymph nodes in comparison to the bigger nanoagents. At
20 min, the GNBs reached the SLN and were no longer observed within the draining lymphatic
vessel. Within one hour post injection, the contrast ratio of the lymphnodes with the surrounding
blood vessels was 9:1. These findings were also supported by analytical measurements of the ex
vivo tissue samples. Results indicate that cumulative nanoparticle deposition in lymph nodes is size
dependent and that high payloads of gold, although offering greater contrast in vitro, may yield
nanoagents with poor intradermal migration and lymphatic transport characteristics.
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In clinics, patients with breast cancer and melanoma presently undergo invasive sentinel lymph
node biopsy (SLNB) to stage metastases. However, even in experienced hands the
identification rates and sensitivities of this technique are less than 95% [1–3]. Moreover, SLNB
can lead to seroma formation, lymphedema, sensory nerve injury, and limitation in the range
of motion [4]. Therefore, an alternative noninvasive method to identify sentinel lymph nodes
(SLNs) in conjunction with either minimally invasive percutaneous fine-needle biopsy
(FNAB) or completely noninvasive molecular techniques will open a whole new prospect of
noninvasive axillary staging for breast cancer. Noninvasive imaging modalities, e.g., magnetic
resonance imaging (MRI), optical imaging, photoacoustic tomography (PAT) in combination
with nanoparticle-based contrast agents show promise in improved detection of metastases.
Among these, PAT is a hybrid biomedical imaging modality, which synergizes the high
contrast of optical imaging with the high resolution of ultrasonic imaging. PAT has been used
for various biomedical applications, such as breast cancer imaging, brain structural and
functional imaging, blood-oxygenation and hemoglobin monitoring, tumor angiogenesis, and,
recently molecular imaging [5–13]. The success of PAT with noninvasive SLNs mapping can
be considered as a giant step towards breast cancer staging.
Noninvasive mapping of SLNs has been explored with photoacoustic (PA) imaging using
various contrast agents, such as methylene blue dye, single-walled carbon nanotubes, gold
nanocages, and gold nanorods [14–17]. While these approaches have seen some preliminary
success in laboratory animals, it is still poorly understood how nanoparticles traverse through
the lymphatic vessels and migrate into the nodes. Clearly, there is a critical unmet clinical need,
and delineating this transport mechanism will further improve detection sensitivities, drug
delivery efficiencies, and reduce off-target toxicity of engineered nanostructures.
We recently reported the development of gold nanobeacons (GNB160s) designed for
noninvasive detection of vascular biosignatures, e.g., fibrin, using photoacoustic tomography
[18]. Colloidal gold nanobeacons represent a nanomedicine platform that have a “soft” nature
and are amenable to bio-elimination, which are essential features for in vivo efficacy and safety.
Ligand-directed GNB160s were found to deliver ten-fold higher PA signal over blood (i.e.,
hemoglobin) when targeted to fibrin clots. We hypothesize that the cumulative nanoparticle
accumulation in lymph nodes is size dependent and that high payloads of metal may yield




Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co.
(St. Louis, MO) and used as received. Anhydrous chloroform and methanol were purchased
from Aldrich Chemical Co. Poly(styrene-b-acrylic acid) [19–22] (PS-b-PAA) was purchased
from Polymer Source Inc. (Montreal, Canada). Biotinylated dipalmitoyl-
phosphatidylethanolamine and high purity egg yolk phosphatidylcholine were purchased from
Avanti Polar Lipids, Inc. Cholesterol and octylthiol-coated gold nanoparticles were purchased
and used as received from Aldrich Chemical Co. (St. Louis, MO). Sorbitan monolaurate was
purchased from Aldrich. Argon and nitrogen (Ultra High Purity: UHP, 99.99%) were used for
storage of materials. The Spectra/Por membrane (Cellulose MWCO: 20 000 Da) used for
dialysis was obtained from Spectrum Medical Industries, Inc. (Laguna Hills, CA).
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In a typical experimental procedure, octanethiol coated gold nanoparticles (2–4 nm, Aldrich
Inc., 2% w/v) in toluene (100 mg) are suspended in sorbitan sesquioleate (4 mL, 2 mole%) and
vigorously vortexed to homogeneity. The suspension was filtered through a small bed of cotton.
The solvent was evaporated under reduced pressure at 45°C. The surfactant co-mixture
included high purity egg yolk phosphatidylcholine (91 mole%, 380 mg), cholesterol (8 mole
%, 17.39 mg), and biotinylated-dipalmitoyl phosphatidylethanolamine (1 mole%, 6.2 mg). The
surfactant co-mixture was dissolved in chloroform, evaporated under reduced pressure, dried
in a 40°C vacuum oven overnight, and dispersed into water by probe sonication. This
suspension was combined with the gold nanoparticle-suspended sorbitan sesquioleate mixture
(20% v/v), distilled deionized water (15.23 mL, 77.3% w/v), and glycerin (0.37 mL, 1.7%, w/
v). The mixture was continuously processed thereafter at 20,000 PSI for 4 minutes with an
S110 Microfluidics emulsifier (Microfluidics) at 4°C. The nanobeacons were dialyzed against
water using a 20,000 Da MWCO cellulose membrane for a prolonged period of time and then
passed through a 0.45 µm Acrodisc Syringe filter. To prevent bacterial growth the nanobeacons
are stored under an argon atmosphere typically at 4°C. DLS (Dav)/nm = 92 ± 13 nm; Zeta (ζ)/
mV = −55 ± 14 mV; AFM (Hav)/nm = 45 ± 10 nm, ICP-MS = 1.56 µg of gold /g of 20%
colloidal suspension.
Preparation of P-GNB290
In a typical experimental procedure, octane thiol coated gold nanoparticles (2–4 nm, Aldrich
Inc.) in toluene were suspended in sorbitan monolaurate (1 mL, 5 mole%) and vigorously
vortexed to homogeneity. The suspension was filtered through a small bed of cotton. The
amphiline PS-b-PAA [19–22] (Mn×10−3: 0.8-b-29.3 polydispersity index: PDI=1.18, 0.0034
mmoles, 104.0 mg, 0.5 mole%) was dissolved in a mixture of methanol and chloroform (4:1),
filtered through a small bed of cotton, evaporated under reduced pressure at 50°C, dried in a
40°C vacuum oven for 6 h, and dispersed into water by probe sonication until a clear suspension
was obtained. This suspension (10 mL) was combined with the gold nanoparticle-suspended
polysorbate mixture (1 mL, 5 mole%), distilled deionized water (8.45 mL, 0.2 µM), and
glycerin (0.45 mL). The mixture was then briefly probe sonicated at ambient temperature
followed by continuous processing at 20,000 PSI (137.9 MPa) for 4 minutes with an S110
Microfluidics emulsifier (Microfluidics) at 4°C. The nanobeacons were purified by exhaustive
dialysis against deionized water using 20 KDa MW CO cellulosic membrane. The
nanoparticles were recovered and passed through a 0.45 µm Acrodisc Syringe filter. To slow
microbial growth the colloids were stored under an argon atmosphere typically at 4°C. DLS
(Dav)/nm = 289 ± 24 nm; Zeta (ζ)/mV = −35 ± 08 mV; AFM (Hav)/nm = 153 ± 31 nm, PDI =
0.15 ± 0.04, ICP-MS = 134 µg of gold /g of 10% colloidal suspension.
Measurements
Dynamic light scattering measurements—Instrument and method: Hydrodynamic
diameter distribution and distribution averages for the GNB and controls in aqueous solutions
were determined by dynamic light scattering. Hydrodynamic diameters were determined using
a Brookhaven Instrument Co. (Holtsville, NY) Model Zeta Plus particle size analyzer.
Measurements were made following dialysis (MWCO 10 kDa dialysis tubing, Spectrum
Laboratories, Rancho Dominguez, CA) of GNB suspensions into deionized water (0.2 µM).
Nanobeacons were dialyzed into water prior to analysis. Scattered light was collected at a fixed
angle of 90°. A photomultiplier aperture of 400 mm was used, and the incident laser power
was adjusted to obtain a photon counting rate between 200 and 300 kcps. Only measurements
for which the measured and calculated baselines of the intensity autocorrelation function agreed
to within +0.1% were used to calculate nanoparticle hydrodynamic diameter values. All
determinations were made in multiples of five consecutive measurements.
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Electrophoretic potential measurements—Instrument and method: Zeta potential (ζ)
values for the gold nanobeacons were determined with a Brookhaven Instrument Co.
(Holtsville, NY) model Zeta Plus zeta potential analyzer. Measurements were made following
dialysis (MWCO 10 kDa dialysis tubing, Spectrum Laboratories, Rancho Dominguez, CA) of
GNB suspensions into water. Data were acquired in the phase analysis light scattering (PALS)
mode following solution equilibration at 25°C. Calculation of ζ from the measured nanoparticle
electrophoretic mobility (µ) employed the Smoluchowski equation: µ= εζ/η, where ε and η are
the dielectric constant and the absolute viscosity of the medium, respectively. Measurements
of ζ were reproducible to within ± 4 mV of the mean value given by 16 determinations of 10
data accumulations.
Atomic Force Microscopy Measurements—Instrument and method: A Digital
Instruments Dimension 3000 series AFM (calibration date 08/2008) and standard Veeco
tapping mode silicon probes w/PtIr coating were used for scanning the samples.
In a typical methodology, aqueous suspensions of GNB samples were dried in a class 10000-
clean room on a clean glass slide for 3 h. Once dried, samples were placed on the AFM and
scanned. Pertinent scanning parameters were as follows: Resonant frequency (probe): 60–80
kHz; Example of tip velocity: (4 um/s for 2 um), (15 um/s for 5 um), (30 um/s for 10 um).
Aspect ratio: 1:1; Lift height: 20 nm; Resolution: 512 samples/line, 256 lines. The average
particle height (Hav) values and standard deviations were generated from the analyses of a
minimum of 100 particles from three micrographs.
Inductively coupled plasma-optical emission spectroscopy (ICP-OES)—
Instrument and method: The iodine and bismuth contents of cROMP were analyzed by
inductively coupled plasma-optical emission spectroscopy (ICP-MS, SOP7040, Rev 9)
conducted at the Bodycote, West Coast Analytical Service (WCAS), Santa Fe Springs, CA.
Briefly, the samples were analyzed by a Leeman Labs Direct Reading Echelle ICP-MS, or a
DRE (Direct Reading Echelle) instrument which was designed to handle sub-ppm to percent
level metal concentrations. DRE consists of a 2 dimensional, high resolution Echelle grating
which precisely and reliably locate any peak in the ICP spectrum.
Photoacoustic Imaging System—Instrument and method: A reflection-mode PA
imaging system [23] was used for all PA experiments. A tunable Ti:sapphire laser (LT-2211A,
LOTIS TII) pumped by Q-switched Nd:YAG (LS-2137, LOTIS II) laser was the light source,
providing <15 ns pulse duration and a 10-Hz pulse repetition rate. A dark-field ring-shaped
illumination was used [24]. The light energy on the sample surface was controlled to conform
to the American National Standards Institute (ANSI) standard for maximum permissible
exposure (MPE) [25]. A 5-MHz central frequency, spherically focused (2.54 cm focus length,
1.91 cm diameter active area element, and 72% bandwidth) ultrasonic transducer (V308,
Panametrics-NDT) was used to acquire the generated PA signals. The signal was then amplified
by a low-noise amplifier (5072PR, Panametrics-NDT), and recorded using a digital
oscilloscope (TDS 5054, Tektronix) with a 50 mega-sampling rate. PA signal fluctuations due
to pulse-to-pulse energy variation were compensated by signals from a photodiode (DET110,
Thorlabs), which sampled the energy of each laser pulse.
A linear translation stage (XY-6060, Danaher Motion) was used for raster scanning to obtain
three-dimensional (3-D) PA data. A computer controlled the stage and synchronized it with
the data acquisition. To shorten the data acquisition time, a continuous scan was used without
signal averaging. An A-line (A-scan) was the PA signal obtained along the depth direction at
a single point. Multiple A-lines (acquired by a one-dimensional (1-D) scan) gave a two-
dimensional (2-D) B-scan. A 3-D image was acquired with a 2-D scan. A 1-D depth-resolved
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image was obtained by multiplying the time axis of the initial A-scan (resolved in time along
the depth direction) by the speed of sound in soft tissue (~1500 m/s).
The scanning time depends on the laser pulse repetition rate (PRR), the scanning step size, and
the field of view (FOV). Typical values are a scanning step size for a 1-D scan = 0.2 mm, for
a 2-D scan = 0.4 mm, a laser PRR = 10 Hz, and a FOV = 24 mm × 24 mm. The acquisition
time = ~25 sec for a B-scan, and = ~18 min for a 3-D image. Please note that no signal averaging
was done for any of these images. The images shown here are cropped to a FOV of 17 mm×21
mm, since the outside region was not of interest. The transducer was located inside a water
container with an opening of 5 cm × 5 cm at the bottom, sealed with a thin, clear membrane.
The object was placed under the membrane, and ultrasonic gel was used for coupling the sound.
The laser power density on the sample surface was ~5 mJ/cm2. For animal studies 767 nm laser
was used. At 767 nm, the MPE on the skin surface by any single laser pulse is ~27 mJ/cm2
[20×102(λ-700)/1000 mJ/cm2], as governed by the ANSI safety standards. Therefore, we were
well within the safety limit. The post-injection images were acquired within 0–5 min after the
injection (denoted as 5 min post-injection image), 20–25 min after injection (denoted as 20
min post-injection image), 40–45 min after injection (denoted as 40 min post-injection image),
60–65 min after injection (denoted as 60 min post-injection image).
Animal and Drug Information—Guidelines on the care and the use of laboratory animals
at Washington University in St. Louis were followed for all animal experiments. Adult Sprague
Dawley rats with body weights ranging from 200–300 g were used for the in vivo studies. Initial
anesthetization of the rat was done using a mixture of ketamine (85 mg/kg) and xylazine (15
mg/kg). The animal was maintained with 1.5–3% isoflurane in oxygen on a ventilator for
approximately 2 h during the SLN imaging, which included a control image (preinjection PA
signal), followed by post-injection PA image at an interval of ~20 min after injection of
GNB160s/ L-GNB90s/ P-GNB290s. For the noninvasive PA imaging, the hair on the region of
interest of the rat was gently removed before imaging, using a commercial hair-removal lotion.
A 0.15 ml of GNB160s/ L-GNB90s/ P-GNB290s was intradermally injected on a left/right
forepaw pad, depending on which side was imaged. PA images were acquired after the
administration of GNBs. During the image acquisition, anesthesia was maintained using
vaporized isoflurane (1 L/min oxygen and 0.75% isoflurane, Euthanex Corp.), and a pulse
oximeter (NONIN Medical INC., 8600V) was used to monitor the vitals. If needed, 8 ml of
0.9% saline was administered to the rat for hydration. After image acquisition, the animal was
euthanized by pentobarbital overdose.
RESULTS AND DISCUSSION
In the first phase of our experiment, the potential of SLN imaging with GNB160 [Dav(DLS):
155 ± 11 nm, ICP-OES: 6120 gold/nanobeacons] was tested in a rodent model. Lymph node
imaging was possible with GNB160 (5 µM) (Fig. 3A and B), however with eight times diluted
GNB160s (~600 nM), SLNs were not visible (see supporting information for more details). The
study produced mixed results with overall unsatisfactory lymph node detection sensitivity.
Our preliminary approach to resolve this issue was to increase the amount of metal within the
colloidal nanobeacons. Towards this aim, we prepared polymer-encapsulated gold
nanobeacons (P-GNB290s) adopting a unique approach, which is based on the self-assembly
of amphiphilic di-block copolymer in aqueous media to entrap high payloads of gold. In a
typical synthesis, PS-b-PAA [19–22] (Mn × 10−3: 0.8-b-29.3, PDI = 1.18, 0.0033 mmoles)
was dissolved in a mixture of methanol and CHCl3 (4:1) and subjected to controlled
evaporation under reduced pressure to generate a thin film of polymer (Fig. 1A). The thin film
was dispersed in deionized water (0.2 µM) by probe sonication at ambient temperature.
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Octanethiol coated AuNPs (2 w/v%) were suspended in polysorbate (sorbitan monolaureate
(5 vol%) and microfluidized with a PS-b-PAA dispersion (0.5 vol%) to obtain the P-GNB290
particles. The nanobeacons were purified by exhaustive dialysis against an infinite sink of
nanopure water using a cellulosic dialysis membrane (20 kDa MWCO). P-GNB290 was
characterized by multiple techniques. Hydrodynamic particle sizes for the P-GNB290 were 289
± 24 nm observed by dynamic light scattering measurements with narrow distribution
(polydispersity indexes, PDI = 0.15 ± 0.04) (Fig. 1B). The particle stability and successful
amphiline-encapsulation were confirmed by the presence of negative electrophoretic potential
(ζ) values. Anhydrous state morphology of the particles was observed by atomic force
microscopy (AFM) studies (Fig. 1C). Gold content was determined by ICP-OES as 134 µg
g−1, which corresponds to 71,493 gold metal atoms per nanobeacon.
Blood (i.e., hemoglobin), which produces a strong PA signal, is a source of intrinsic contrast
inside the human body. Therefore, any material that is capable of generating PA signals
comparable to blood has potential to serve as an extrinsic contrast agent. The use of the near-
infrared (NIR) window for PAT is well known for deep tissue imaging, although image contrast
is reduced. Photoacoustic imaging of P-GNB290 in suspension within the NIR range was
promising. Fig. 2A shows P-GNB290 (680 nM) produced a stronger PA signal than blood (λ
= 767 nm). P-GNB290s produced a peak-to-peak PA signal amplitude of 540 ± 30 mV, whereas
blood produced 133 ± 7 mV. Fig. 2B shows the PA spectrum over wavelengths from 721 to
823 nm. P-GNB290s produced a PA signal at least two times stronger than blood. The PA signal
amplitude changed as the concentration of nanobeacons was varied. Fig. 2C shows how the
PA signal amplitude changed for several laser wavelengths from serially diluted P-GNB290s.
It is evident that a significant PA signal was produced even at the low concentration of 10 nM,
making P-GNB290s a candidate for in vivo applications.
The potential of SLN imaging with the use of P-GNB290s was explored through fore-paw
injection in a rat model. Interestingly, SLN imaging with P-GNB290s (680 nM) was
unsuccessful. Fig. 3C and D show the pre- (control) and post-injection (60 min) maximum
amplitude projection (MAP) [8] photoacoustic images. SLNs were dynamically monitored for
three days without promising results (n = 4). This confirmed that we were not experiencing a
slower, longer-lasting transport of these larger nanobeacons into the lymphatic vessels. These
results led us to believe that the uptake of the P-GNB290s in the lymphatic channels and
transport to the lymph node were poor, which presumembly were correlated with the larger
size and mass of these gold nanobeacons (> 250 nm).
The unsuccessful outcome prompted us to explore a smaller lipid-encapsulated (~90 nm) gold
nanobeacon (L-GNB90) (Fig. 1A). Gold nanoparticles (AuNPs) were uniquely suspended
within a polysorbate core matrix to avoid unfavorable interactions with the surrounding plasma
proteins. In a typical procedure, octanethiol-functionalized, coated AuNPs (2 w/v% of inner
matrix) were suspended in polysorbate (sorbitan monolaureate, 20 vol%) and homogenized
with the surfactant mixture at 137.9 MPa for 4 min to produce L-GNB90s. The surfactant
mixture comprised mainly of phosphatidylcholine (PC) (~90 mol% of lipid constituents).
Hydrodynamic particle sizes for the L-GNB90s were 92 ± 12 nm (DLS) with narrow
polydispersity indexes, PDI = 0.35 ± 0.05 (Fig. 1B). Anhydrous state particle heights were
measured to be 45 ± 10 nm (Fig. 1C). Gold content was determined by ICP-OES as 1.56 µg
g−1, corresponding to approximately 9 gold metal atoms per L-GNB90s.
Fig. 2 summarizes the feasibility of using L-GNB90s as NIR contrast agents. Fig. 2A shows
that L-GNB90s (10 nM) produced a stronger PA signal than blood (λ = 767 nm). L-GNB90s
produced a peak-to-peak PA signal amplitude of 168 ± 12 mV. Interestingly, L-GNB90s
produced a stronger PA signal than blood below 795 nm wavelength but a weaker one above
800 nm. L-GNB90s produced weaker PA signals in suspension than P-GNB290s, presumably
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due to its incorporation of much lower concentrations of gold. Although L-GNB90s have a
weaker absorption coefficient than P-GNB290s in the NIR wavelength range, they were still
considered useful for in vivo SLN imaging application.
The efficacy of L-GNB90s for SLN imaging was studied in a rat model following intradermal
injection of the particles, as used previously. At baseline, sagittal MAP photoacoustic image
(resolution = ~500 µm, in plane) of the axillary area revealed a distinct microvasculature
indicated by the red arrows (Fig. 3E). Lymph nodes were undetectable at baseline, lacking any
intrinsic optical absorbers, in contradistinction to the adjacent blood vessels containing highly
absorbing red blood cells. Following baseline image acquisition, L-GNB90s (150 µL) were
injected intradermally into the forepaw, and serial PA images were acquired. At 5 and 20 mins
post-injection, sentinel lymphnodes were easily visualized (Fig. 3F and G). In Fig. 3F,
immediately after the injection, L-GNB90s were noted traveling through the lymphatic system
(designated by the blue arrow) and accumulating in the lymphnodes. At 20 min, the L-
GNB90s had reached the SLNs and were no longer observed within the draining lymphatic
vessel. Dynamic PA imaging was performed up to 1 hour post-injection, and SLNs remained
visible in all the PA images (see supporting information for more details). The blood vessels
and the SLN were detected with a contrast of 12 and 89, respectively (calculated from the 1
hour post-injection MAP image). The contrast is defined as the ratio of the average PA signal
amplitude obtained from the blood vessel/SLN to the average background signal amplitude.
Thus the contrast ratio between the SLN and the surrounding blood vessel was ~7.5:1. The
signal-to-noise ratio (SNR) was 24 dB and 39 dB for blood vessels and SLN, respectively. The
SNR, calculated from the raw A-line signal without any signal averaging, was defined as
20*log (peak signal amplitude/standard deviation of background). Fig. 3H illustrates the same
image as in Fig. 3G, with two different color maps (green for the contribution from the
nanobeacons, red for hemoglobin). Some of the nanobeacons transited into the surrounding
vessels, as evident from the signal therein. An optical photograph of the excised lymph node
is shown in Fig. 3K. Subsequent dissection of the lymph node revealed no outwardly visible
accumulation of AuNP themselves (i.e., red color) indicating the patent integrity of the surface
lipid coating.
The above experiment was successfully repeated with diluted L-GNB90s (2.5 and 1 nM). In
both cases, lymph nodes were clearly visible (Fig. 3I–J and 3M–N) in the post-injection (5
min) MAP photoacoustic image. We quantified the signal intensities and observed a ~9 times
enhancement with L-GNB90s injection, ~7.5 times enhancement with 1/4x diluted L-
GNB90s, ~5.2 times enhancement with 1/10x diluted L-GNB90s, and ~2.6 times enhancement
with GNB160s. However, with P-GNB290s no signal enhancement was seen after injection
(average signal is ~1.01 times the pre-injection value). As a result, we concluded that SLNs
mapping with P-GNB290s was infeasible. The total gold content of the excised lymphnode
specimens were analytically determined by ICP-OES as 8.74 µg g-1 and 1.99 µg g-1, (detection
limit =0.02 µg g-1), for animals injected with L-GNB90s and P-GNB290s respectively.
CONCLUSIONS
In summary, both GNB160s and L-GNB90s can function as contrast agents for PA deep tissue
imaging in the NIR window, with the smaller L-GNB90s being superior for SLNs detection.
Although L-GNB90s had lower PAT contrast in suspension, in vitro than GNB160s or P-
GNB290s, when injected intradermally L-GNB90s travel quickly through the lymphatic vessels
and migrate exclusively to the lymph nodes. P-GNB290s produced strong PA signals in
suspension and therefore could be beneficial for other in vivo application. These results suggest
that cumulative nanoparticle deposition in lymph nodes is size dependent and that high
payloads of gold, although offering greater contrast, may yield nanoagents with poor
intradermal migration and lymphatic transport characteristics.
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Appendix
Fig. S1–S5: UV-vis spectroscopic profile of gold nanobeacons, in vivo photoacoustic images
of sentinel lymph nodes of rat, B-scan PA image showing the depth of the lymph nodes in rat.
These materials can be found in the online version.
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A. Synthesis of GNBs. B. Physico-chemical characterization. C. Anhydrous state AFM images
(drop-deposited on glass). [Dav= Number averaged (DLS); ζ= electrophoretic (zeta) potential;
Hav= average height (AFM); PDI= polydispersity index (DLS); ICP (Au)= analytical gold
content (ICP-OES)., height scale expressed in nm].
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A. Photoacoustic (PA) signals generated from a tube (Silastic® laboratory tubing, Dow
Corning Corp., I.D. 300 µm, O.D. 640 µm) filled with P-GNB290s (680 nM), L-GNB90s (10
nM), and blood at λ = 767 nm. B. PA spectrum of P-GNB290s, L-GNB90s, and blood. C. PA
signal of serially diluted P-GNB290s at various wavelengths.
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In vivo noninvasive photoacoustic imaging of sentinel lymph nodes in rat (λ = 767 nm). (A–J,
M–N) Scale bar is 5 mm. 150 µL of nanobeacons were injected intradermally in all the cases.
GNB160: A. Control PA image. B. 5 min post-injection image of GNB160s (5 µM).
P-GNB290: C. Control PA image. D. Lymph node is not visible in a 60 min post-injection
image of P-GNB290s (680 nM).
L-GNB90: E. Sagittal maximum amplitude projection (MAP) [8] pre-injection control image:
Bright parts represent optical absorption from blood vessels, marked with red arrows. F. PA
image (MAP) acquired 5 min after L-GNB90 injection (10 nM). SLNs are clearly visible,
marked with green arrow. Lymphatic vessel is also visible, marked with blue arrow. G. 20 min
post-injection PA image. H. Same as G with two different color spaces showing the blood
vessel as well as the SLNs. I. Control PA image. J. 5 min post-injection image of 4 times diluted
L-GNB90s (2.5 nM). K. Digital optical photograph of the rat with the skin removed after PA
imaging. Lymph node area is shown with green arrow. L. Excised lymph node. Smallest tick:
1 mm. M. Control PA image. N. 5 min post-injection image of 10 times diluted L-GNB90s (1
nM). O. Average PA signal from the ROI (marked as yellow dotted square in all the pre-
injection or control images, 3A, C, E, I, M). Blue represents pre-injection and brown represents
post-injection. Images are normalized by pre-injection signal.
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